Immunomodulatory effects of the tobacco-specific carcinogen, NNK, on alveolar macrophages

Clinical and Experimental Immunology

Volumn 132, Issue 2, 2003, Pages 232-238

  Therriault, M J ^a   Proulx, L I ^a   Castonguay, A ^b   Bissonnette, E Y ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Alveolar macrophages; Cytokines; NNK metabolism; Prostaglandin

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANOL; 4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CARBONYL DERIVATIVE; CARCINOGEN; IMMUNOMODULATING AGENT; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NITRIC OXIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYLATION; IMMUNOMODULATION; LUNG ALVEOLUS MACROPHAGE; LUNG CARCINOMA; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; SUPERNATANT; TOBACCO;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOGENS; CELL LINE; CYCLOOXYGENASE INHIBITORS; DEPRESSION, CHEMICAL; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOMETHACIN; INTERLEUKIN-10; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; MACROPHAGE INFLAMMATORY PROTEIN-1; MACROPHAGES, ALVEOLAR; NITRIC OXIDE; NITROBENZENES; NITROSAMINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SMOKING; SULFONAMIDES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0038555677     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02142.x     Document Type: Article

References (35)

1. Williams MD, Sandler AB. The epidemiology of lung cancer. Cancer Treat Res 2001; 105:31-52.
2. Wynder EL. Tobacco as a cause of lung cancer: some reflections. Am J Epidemiol 1997; 146:687-94.
3. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91:1194-210.
4. Hecht SS. Biochemistry, biology and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 1998; 11:560-603.
5. Smith TJ, Stoner GD, Yang CS. Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochrome P450, lipoxygenase and hydroperoxides. Cancer Res 1995; 55:5566-73.
6. Rioux N, Castonguay A. Induction of COXs expression by a tobacco carcinogen: implication of lung cancer chemoprevention. Inflamm Res 1999; 48 (Suppl. 2):136-7.
7. Hecht SS, Carmella SG, Foiles PG, Murphy SE, Peterson LA. Tobacco-specific nitrosamines adducts: studies in laboratory animals and humans. Environ Health Perspec 1993; 99:57-63.
8. Kraal G, Broug E, Thepen T, Van Iwaarden JF, Persoons JHA. The role of alveolar macrophages in pulmonary immune function. In: Lipscomb MF, Russell SW, eds. Lung Macrophages and Dendritic Cells in Health Disease. New York: Marcel Dekker Inc., 1997:203-20.
9. Cavaillon JM. Cytokines and macrophages. Biomed Pharmacother 1994; 48:445-53.
10. Hirano S. Nitric oxide-mediated cytotoxic effects of alveolar macrophages on transformed lung epithelial cells are independent of the beta 2 integrin-mediated intercellular adhesion. Immunology 1998; 93:102-8.
11. Hendrzak JA, Brunda MJ. Biology of disease. Interleukin-12, biologic activity, therapeutic utility, and role in disease. Lab Invest 1995; 72:619-37.
12. De Vita F, Orditura M, Galizia G et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 2000; 117:365-73.
13. Huang M, Wang J, Lee P et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 1995; 55:3847-53.
14. Harris JO, Swenson EW, Johnson JE. Human alveolar macrophages. Comparison of phagocytic ability, glucose utilization, and ultrastructure in smokers and nonsmokers. J Clin Invest 1970; 49:2086-96.
15. Thomassen MJ, Wiedemann HP, Barna BP, Farmer M, Abroad M. Induction of in vitro tumoricidal activity in alveolar macrophages. Cancer Res 1988; 48:3949-53.
16. Brown GP, Iwamoto GK, Monick MM, Hunninghake GW. Cigarette smoking decreases interleukin 1 release by human alveolar macrophages. Am J Physiol 1989; 256:C260-4.
17. McCrea KA, Ensor JE, Nall K, Bleecker ER, Hasday JD. Altered cytokine regulation in the lung of cigarette smokers. Am J Respir Crit Care Med 1994; 150:696-703.
18. Brown R, Pinkerton R, Tuttle M. Respiratory infections in smokers. Am Faro Physician 1987; 36:133-40.
19. 3 receptors. Stimulation of IL-10 production. J Immunol 2000; 164:2964-70.
20. Rioux N, Castonguay A. 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone modulation of cytokine release in U937 human macrophages. Cancer Immunol Immunother 2001; 49:663-70.
21. 4. Potentiation of inflammation. Am J Respir Cell Mol Biol 2000; 23:572-7.
22. Schrader E, Hirsch-Ernst KI, Richter E, Foth H. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in isolated rat lung and liver. Naunyn-Schmiedeberg's Arch Pharmacol 1998; 357:336-43.
23. Smith GBJ, Castonguay A, Donnelly PJ, Reid KR, Petsikas D, Massey E. Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells. Carcinogenesis 1999; 20:1809-18.
24. Fischer S, Castonguay A, Kaiserman K, Spiegelhalder B, Preussmann R. Tobacco-specific nitrosamines in Canadian cigarettes. J Cancer Res Clin Oncol 1990; 116:563-8.
25. Fischer S, Spiegelhalder B, Preussmann R. Tobacco-specific nitrosamines in European and USA cigarettes. Arch Geschwulstforsch 1990; 60:169-77.
26. Standiford TJ, Kunkel SL, Greenberger MJ, Laichalk LL, Strieter RM. Expression and regulation of chemokines in bacterial pneumonia. J Leukoc Biol 1996; 59:24-8.
27. Taub DD, Ortaldo JR, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol 1996; 59:81-9.
28. MacMicking J, Xie Q-W, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15:323-50.
29. Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ. Acute and chronic effects of cigarette smoking on exhaled nitric oxide. Am J Respir Crit Care Med 1995; 152:609-12.
30. de Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin 10. Ann Med 1995; 27:537-41.
31. Nabioullin R, Sone S, Mizuno K et al. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J Leukoc Biol 1994; 55:437-42.
32. Spagnoli GC, Juretic A, Schultz-Thater E et al. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity. Cell Immunol 1993; 146:391-405.
33. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998; 58:5353-60.
34. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997; 49:15-9.
35. Howe LR, Subbaramaiah K, Brown AMC, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001; 8:97-114.